Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded...

Area of Science:

• Molecular Biology
• Gene Regulation
• Biotechnology

Background:

• Tetracycline resistance regulatory elements from E. coli were adapted for eukaryotic gene expression.
• The rtTA system, a tetracycline-controlled transactivator, requires doxycycline for P(tet) promoter activation but has limitations like inefficient inducibility and background activity.

Purpose of the Study:

• To overcome limitations of the existing rtTA system by developing mutants with reduced basal activity and increased doxycycline sensitivity.
• To create novel rtTA variants with improved stability and tighter transcriptional control for use in eukaryotic systems, including transgenic animals.

Main Methods:

• Mutagenesis of tTA DNA and selection in Saccharomyces cerevisiae to identify improved rtTA mutants.
• Optimization of coding sequences for expression in human cells and synthesis of new transactivators.
• Testing of new rtTA variants in stably transfected HeLa cells for regulatory range and stringency.

Main Results:

• Five new rtTA mutants were identified, with two showing significantly improved properties.
• The rtTA2(S)-M2 transactivator demonstrated 10-fold lower doxycycline concentration requirement, enhanced stability, and no background expression.
• Optimized rtTA versions enabled stringent gene regulation over 4-5 orders of magnitude in HeLa cells.

Conclusions:

• Novel rtTA variants, particularly rtTA2(S)-M2, offer superior performance compared to existing systems.
• These improved transactivators provide tight expression control and a broad regulatory range, suitable for various eukaryotic applications.
• The developed rtTA versions address key limitations, enhancing their utility in gene expression studies and biotechnology.